Jan H Beumer

List of Publications by Year
in descending order

159	4,704	76196	128067
papers	citations	40 h-index	60 g-index

164	164	164	7891
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 1726-1734.	3.2	186
2	Sulforaphane Inhibits Prostate Carcinogenesis and Pulmonary Metastasis in TRAMP Mice in Association with Increased Cytotoxicity of Natural Killer Cells. Cancer Research, 2009, 69, 2117-2125.	0.4	177
3	Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemotherapy and Pharmacology, 2016, 78, 447-464.	1.1	149
4	ATR kinase inhibitor AZD6738 potentiates CD8+ T cellâ€“dependent antitumor activity following radiation. Journal of Clinical Investigation, 2018, 128, 3926-3940.	3.9	136
5	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro-Oncology, 2015, 17, 992-998.	0.6	116
6	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncology, The, 2014, 15, 87-95.	5.1	113
7	ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research, 2014, 20, 2703-2713.	3.2	105
8	In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 715-727.	1.3	96
9	Chemopreventative Potential of the Cruciferous Vegetable Constituent Phenethyl Isothiocyanate in a Mouse Model of Prostate Cancer. Journal of the National Cancer Institute, 2011, 103, 571-584.	3.0	94
10	Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. Journal of Clinical Oncology, 2010, 28, 4507-4512.	0.8	87
11	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical Cancer Research, 2017, 23, 4066-4076.	3.2	87
12	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/orBRCAMutationâ€“Associated Breast Cancer. Clinical Cancer Research, 2016, 22, 2855-2864.	3.2	80
13	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer, 2009, 115, 2188-2198.	2.0	79
14	Mass Balance Studies, with a Focus on Anticancer Drugs. Clinical Pharmacokinetics, 2006, 45, 33-58.	1.6	77
15	Clove Extract Inhibits Tumor Growth and Promotes Cell Cycle Arrest and Apoptosis. Oncology Research, 2014, 21, 247-259.	0.6	77
16	Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5â€Fluorouracil Therapy. Clinical Pharmacology and Therapeutics, 2019, 105, 598-613.	2.3	77
17	Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Medicine, 2014, 3, 1579-1594.	1.3	74
18	Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production. Immunity, 2019, 50, 51-63.e5.	6.6	74

#	Article	IF	Citations
19	Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2â€²-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemotherapy and Pharmacology, 2008, 62, 363-368.	1.1	67
20	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	0.8	66
21	ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage. Nucleic Acids Research, 2013, 41, 10334-10344.	6.5	63
22	Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment. Current Clinical Pharmacology, 2010, 5, 196-208.	0.2	62
23	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer â€“ An NRG oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 144, 459-467.	0.6	61
24	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prevention Research, 2018, 11, 429-438.	0.7	59
25	Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. British Journal of Clinical Pharmacology, 2009, 68, 370-374.	1.1	58
26	A liquid chromatographyâ€“electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 840, 108-115.	1.2	56
27	Quantitation of 5â€fluorouracil (5â€FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 224-230.	0.7	56
28	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clinical Cancer Research, 2017, 23, 697-706.	3.2	56
29	Modulation of Gemcitabine (2â€²,2â€²-Difluoro-2â€²-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine. Clinical Cancer Research, 2008, 14, 3529-3535.	3.2	55
30	Estimation of Kidney Function in Oncology. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 587-595.	2.2	54
31	Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2â€²-Deoxycytidine in Mice. Clinical Cancer Research, 2006, 12, 7483-7491.	3.2	51
32	A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2â€²-deoxycytidine, administered with tetrahydrouridine. Cancer Chemotherapy and Pharmacology, 2015, 75, 537-546.	1.1	50
33	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. Journal of Clinical Oncology, 2019, 37, 2601-2609.	0.8	50
34	Without Therapeutic Drug Monitoring, There Is No Personalized Cancer Care. Clinical Pharmacology and Therapeutics, 2013, 93, 228-230.	2.3	49
35	The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. OncoTargets and Therapy, 2014, 7, 969.	1.0	49
36	A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anti-Cancer Drugs, 2013, 24, 743-753.	0.7	47

#	Article	IF	Citations
37	Body-Surface Areaâ€“Based Chemotherapy Dosing: Appropriate in the 21st Century?. Journal of Clinical Oncology, 2012, 30, 3896-3897.	0.8	46
38	Effect of antacid on imatinib absorption. Cancer Chemotherapy and Pharmacology, 2009, 63, 525-528.	1.1	44
39	Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 1838-1851.	3.2	44
40	CYP24 inhibition preserves 1Î±,25-dihydroxyvitamin D3 anti-proliferative signaling in lung cancer cells. Molecular and Cellular Endocrinology, 2012, 355, 153-161.	1.6	42
41	Targeting p53-dependent stem cell loss for intestinal chemoprotection. Science Translational Medicine, 2018, 10, .	5.8	41
42	Multicenter Evaluation of a Novel Nanoparticle Immunoassay for 5-Fluorouracil on the Olympus AU400 Analyzer. Therapeutic Drug Monitoring, 2009, 31, 688-694.	1.0	40
43	Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 856-865.	0.5	39
44	Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. Cancer Chemotherapy and Pharmacology, 2017, 79, 201-207.	1.1	39
45	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clinical Cancer Research, 2018, 24, 5830-5840.	3.2	36
46	Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid Leukemia. Pharmacotherapy, 2009, 29, 1152-1156.	1.2	35
47	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 73-81.	1.1	32
48	Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model. Journal of Surgical Research, 2012, 178, 545-552.	0.8	31
49	Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. Lancet Oncology, The, 2021, 22, 1333-1340.	5.1	31
50	Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS ONE, 2015, 10, e0134426.	1.1	30
51	Disposition of Imatinib and Its Metabolite CGP74588 in a Patient with Chronic Myelogenous Leukemia and Short-Bowel Syndrome. Pharmacotherapy, 2006, 26, 903-907.	1.2	29
52	Metabolism of trabectedin (ET-743, Yondelisâ„¢) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2007, 59, 825-837.	1.1	29
53	A high-performance liquid chromatographyâ€“mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1894-1900.	1.2	29
54	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 197-205.	1.4	29

#	Article	IF	Citations
55	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemotherapy and Pharmacology, 2019, 84, 1289-1301.	1.1	29
56	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomaterialia, 2020, 106, 289-300.	4.1	29
57	Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model. Journal of the National Cancer Institute, 2012, 104, 1228-1239.	3.0	28
58	Disease Subtypeâ€"Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A. Journal of the National Cancer Institute, 2017, 109, djw293.	3.0	28
59	Liquid chromatographyâ€"mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 872, 141-147.	1.2	27
60	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemotherapy and Pharmacology, 2014, 74, 927-938.	1.1	27
61	Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Programâ€"Sponsored Single-Agent Phase I Studies. Journal of Clinical Oncology, 2016, 34, 110-116.	0.8	27
62	Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinibâ€"an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer. Drug Metabolism and Disposition, 2013, 41, 1843-1851.	1.7	23
63	Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer. Molecular Cancer Therapeutics, 2013, 12, 1545-1555.	1.9	23
64	LCâ€"MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 130-136.	1.4	23
65	Biotransformation Profiling of [14C]Ixabepilone in Human Plasma, Urine and Feces Samples Using Accelerator Mass Spectrometry (AMS). Drug Metabolism and Pharmacokinetics, 2009, 24, 511-522.	1.1	22
66	In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. Cancer Chemotherapy and Pharmacology, 2013, 71, 331-344.	1.1	22
67	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia and Lymphoma, 2020, 61, 309-317.	0.6	22
68	Human mass balance study of TAS-102 using 14C analyzed by accelerator mass spectrometry. Cancer Chemotherapy and Pharmacology, 2016, 77, 515-526.	1.1	21
69	Precision Dosing of Targeted Therapies Is Ready for Prime Time. Clinical Cancer Research, 2021, 27, 6644-6652.	3.2	21
70	Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemotherapy and Pharmacology, 2008, 62, 457-64.	1.1	20
71	Analytical challenges in quantifying abiraterone with LCâ€"MS/MS in human plasma. Biomedical Chromatography, 2017, 31, e3986.	0.8	20
72	Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. Clinical Colorectal Cancer, 2007, 6, 407-422.	1.0	19

#	Article	IF	Citations
73	Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 167, 469-478.	1.1	19
74	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer Chemotherapy and Pharmacology, 2020, 85, 741-751.	1.1	19
75	Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemotherapy and Pharmacology, 2012, 69, 1657-1667.	1.1	18
76	VDR Activity Is Differentially Affected by Hic-5 in Prostate Cancer and Stromal Cells. Molecular Cancer Research, 2014, 12, 1166-1180.	1.5	17
77	Parentâ€Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABTâ€888), a PARP Inhibitor, in Patients With BRCA 1/2â€“Mutated Cancer or PARPâ€Sensitive Tumor Types. Journal of Clinical Pharmacology, 2017, 57, 977-987.	1.0	17
78	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 236-242.	0.6	17
79	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	3.2	17
80	Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. Journal of Neuro-Oncology, 2009, 93, 279-283.	1.4	16
81	A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer Chemotherapy and Pharmacology, 2012, 70, 843-853.	1.1	16
82	Oral and intravenous pharmacokinetics of 5-fluoro-2â€²-deoxycytidine and THU in cynomolgus monkeys and humans. Cancer Chemotherapy and Pharmacology, 2015, 76, 803-811.	1.1	16
83	Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. Cancer Chemotherapy and Pharmacology, 2015, 76, 813-819.	1.1	16
84	Improving Carboplatin Dosing Based on EstimatedÂGFR. American Journal of Kidney Diseases, 2018, 71, 163-165.	2.1	16
85	Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. Clinical Cancer Research, 2021, 27, 1612-1622.	3.2	16
86	A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX phosphorylation in human peripheral blood mononuclear cells. Oncoscience, 2015, 2, 542-554.	0.9	16
87	LCâ€“MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2013, 81-82, 89-98.	1.4	15
88	Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Scientific Reports, 2017, 7, 41892.	1.6	15
89	A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 145, 291-297.	0.6	15
90	Antiâ€“Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 373-380.	2.0	15

#	Article	IF	Citations
91	Liquid chromatographyâ€“tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 714-720.	1.4	14
92	A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D3 is revealed using a novel LCâ€“MS/MS assay. Steroids, 2012, 77, 477-483.	0.8	14
93	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 2019, 85, 2499-2511.	1.1	14
94	Radiation therapy induces the DNA damage response in peripheral blood. Oncotarget, 2013, 4, 1143-1148.	0.8	14
95	Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews. Cancer Chemotherapy and Pharmacology, 2015, 75, 143-152.	1.1	13
96	Intravenous 5-fluoro-2â€²-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 979-993.	1.1	13
97	Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 831, 147-155.	1.2	12
98	Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743). Current Clinical Pharmacology, 2009, 4, 38-42.	0.2	12
99	Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2007, 21, 1991-1997.	0.7	11
100	Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma. BMC Cancer, 2015, 15, 649.	1.1	11
101	Phase I study of veliparib in combination with gemcitabine. Cancer Chemotherapy and Pharmacology, 2017, 80, 631-643.	1.1	11
102	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castrationâ€“Resistant Prostate Cancer. Therapeutic Drug Monitoring, 2018, 40, 222-229.	1.0	11
103	Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy. Sarcoma, 2019, 2019, 1-9.	0.7	11
104	Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemotherapy and Pharmacology, 2019, 84, 1201-1208.	1.1	11
105	A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemotherapy and Pharmacology, 2016, 77, 333-338.	1.1	10
106	A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2595-2601.	0.6	10
107	A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo. Blood, 2013, 122, 684-684.	0.6	10
108	A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice. Clinical Cancer Research, 2006, 12, 5826-5833.	3.2	9

#	Article	IF	Citations
109	Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemotherapy and Pharmacology, 2011, 67, 421-430.	1.1	9
110	Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 959-967.	1.1	9
111	Population pharmacokinetics and exposureâ€“response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. Cancer Chemotherapy and Pharmacology, 2019, 83, 319-328.	1.1	9
112	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances, 2021, 5, 4691-4700.	2.5	9
113	Liquid chromatographyâ€“mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 168-174.	1.2	8
114	LCâ€“MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2016, 129, 359-366.	1.4	8
115	Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	8
116	Evaluation of Different Formulations and Routes for the Delivery of the Ionizing Radiation Mitigator GS-Nitroxide (JP4-039). In Vivo, 2018, 32, 1009-1023.	0.6	8
117	Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 26-32.	1.4	8
118	In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. Journal of Extra-Corporeal Technology, 2010, 42, 75-9.	0.2	8
119	Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2013, 72, 1143-1147.	1.1	7
120	Human hepatocyte assessment of imatinib drugâ€“drug interactions â€“ complexities in clinical translation. British Journal of Clinical Pharmacology, 2015, 80, 1097-1108.	1.1	7
121	An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma. Therapeutic Drug Monitoring, 2015, 37, 486-492.	1.0	7
122	A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent. Clinical Cancer Research, 2015, 21, 721-729.	3.2	7
123	Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. Cancer Chemotherapy and Pharmacology, 2016, 78, 1225-1235.	1.1	7
124	Liquid chromatographyâ€“tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 169-175.	1.4	7
125	A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 473-482.	1.1	7
126	Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. Cancer Chemotherapy and Pharmacology, 2013, 72, 1195-1204.	1.1	6

#	Article	IF	Citations
127	Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinibâ€"a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. Journal of Clinical Pharmacology, 2014, 54, 1272-1279.	1.0	6
128	ATM serine-1981 phosphorylation is a plausible biomarker. Cell Cycle, 2015, 14, 3207-3208.	1.3	6
129	Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. Translational Research, 2021, 229, 100-114.	2.2	6
130	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 721-735.	1.1	5
131	Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines. Cancer Chemotherapy and Pharmacology, 2013, 71, 73-83.	1.1	4
132	Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612). Cancer Chemotherapy and Pharmacology, 2015, 76, 537-546.	1.1	4
133	LCâ€"MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 158-165.	1.4	4
134	Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2017, 39, 235-242.	1.0	4
135	Estimation of body surface area in the musk shrew (Suncus murinus): a small animal for testing chemotherapy-induced emesis. Laboratory Animals, 2017, 51, 534-537.	0.5	4
136	Quantitation of iohexol, a glomerular filtration marker, in human plasma by LCâ€"MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2020, 189, 113464.	1.4	4
137	Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2014, 73, 207-211.	1.1	3
138	Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs. Cancer Chemotherapy and Pharmacology, 2015, 75, 1015-1023.	1.1	3
139	RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology. DNA Repair, 2017, 52, 24-30.	1.3	3
140	LCâ€"MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 154-160.	1.4	3
141	In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Cancer Chemotherapy and Pharmacology, 2020, 86, 633-640.	1.1	3
142	Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. Cancer Chemotherapy and Pharmacology, 2020, 86, 535-545.	1.1	3
143	ALDH1A1 Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper. Sarcoma, 2022, 2022, 1-12.	0.7	3
144	Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer Chemotherapy and Pharmacology, 2022, 89, 231-242.	1.1	3

#	Article	IF	Citations
145	In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4â€“p53 interaction. Cancer Chemotherapy and Pharmacology, 2015, 76, 287-299.	1.1	2
146	LCâ€“MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 244-250.	1.4	2
147	Quantitation of Cabozantinib in Human Plasma by LCâ€“MS/MS. Journal of Chromatographic Science, 2022, 60, 274-279.	0.7	2
148	Development and validation of an LCâ€“MS/MS generic assay platform for small molecule drug bioanalysis. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114185.	1.4	2
149	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. Cancer Chemotherapy and Pharmacology, 2022, 89, 49-58.	1.1	2
150	Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 199-204.	1.4	1
151	Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features. Clinical Genitourinary Cancer, 2017, 15, 7-22.	0.9	1
152	Editorial. Cancer Chemotherapy and Pharmacology, 2020, 85, 1-1.	1.1	1
153	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2021, 88, 643-654.	1.1	1
154	Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice. Current Reviews in Clinical and Experimental Pharmacology, 2021, 16, 263-272.	0.4	1
155	Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice. Cancer Chemotherapy and Pharmacology, 2022, , 1.	1.1	1
156	Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area. JAMA Oncology, 2015, 1, 732.	3.4	0
157	Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. Journal of Clinical Oncology, 2016, 34, 2430-2431.	0.8	0
158	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. Blood, 2011, 118, 1986-1986.	0.6	0
159	A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC).. Journal of Clinical Oncology, 2012, 30, 283-283.	0.8	0